Surety Medicine 
Surety site workers may require PPE use tests for maximum safety.  US ARMY photo 

Use tests can be important to ensure maximum safety for surety site personnel requiring
personal protective equipment in their work environments.    
                                                                                                                         -US ARMY Photo

January 2017 Surety Medicine Teleconference:

RESPIRATOR CLEARANCE AND PERSONAL
PROTECTIVE EQUIPMENT:
The Role of Use Testing 

WEDNESDAY, 25 January 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time.  The topic for January will be “Respirator Clearance and Personal Protective Equipment Assessments:  The Role of Use Testing.”  The presenter will be a physician who is board certified in internal and pulmonary medicine with extensive experience in toxic inhalation injuries and surety site worker requirements.  Please note the January  teleconference is occurring on the fourth Wednesday of the month rather than the third Wednesday to prevent schedule conflicts.

To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:

usarmy.apg.medcom-aphc.mbx.surety-medicine@mail.mil

______________________________________________________________

SCHEDULE OF SURETY MEDICINE
TELECONFERENCES FOR FY 2017

 Date           Topic                                                                                               

25 JAN 2017

Respiratory Clearance and PPE Assessments: 
The Role of Use Testing

15 FEB 2017

Regulatory Policy Updates in Surety Medicine

15 MAR 2017

Peripheral Vascular Disease, DVT, and Anticoagulation—
Assessing PRP Suitability

19 APR 2017

Abuse, Dependence and Substance Use Disorders: 
DSM-IV-TR vs. DSM-5

17 MAY 2017

Screening for Active TB or LTBI:  TB Skin tests vs. Alternatives

21 JUN 2017

Heat Stress Prevention and Management Issues
in the Surety Environment

19 JUL 2017

Syncopal Conditions:  Impacts on PRP Reliability

16 AUG 2017

Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA

20 SEP 2017

Obstructive Sleep Apnea:  Screening, Diagnosis,
Treatment and Compliance: 
The PRP Perspective

ALERT:  FDA Simplifies Rule for Anthrax PEP

FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS

The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at: 

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474027.htm  


ALERT:  Autoinjector Shelf Life Extension Program:  Current Information

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019.  Complete FDA information related to the auto-injector shelf life extension program can be found at:  http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .  

Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors. 

_______________________________________________________________